Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee

Table 6 Rates of AOEs non-adjudicated and adjudicated AOEs in CP-CML patients (n = 270)

AOE	Non-adjudicated events^a		Adjudicated events^b
AOE	Any	Serious	Any	Serious
Any,	84 (31)	69 (26)	57 (21)	54 (20)
Cardiovascular^c	42 (16)	33 (12)	26 (10)	25 (9)
Cerebrovascular	35 (13)	28 (10)	25 (9)	22 (8)
Peripheral vascular	38 (14)	31 (11)	31 (11)	26 (10)
Exposure-adjusted newly occurring AOEs, patients with events per 100 patient-years	11.3	9.3	8.7	8.1

Data are no. (%) of patients, unless otherwise specified
AOE arterial occlusive event, CP-CML chronic-phase chronic myeloid leukemia, MedDRA Medical Dictionary for Regulatory Activities, MI myocardial infarction, PT preferred term
^aCategorization of AOEs is based on > 400 MedDRA preferred terms related to vascular ischemia or thrombosis
^bEvents that were adjudicated as an AOE by the adjudication committee
^cDoes not include arterial hypertension AEs

ISSN: 1756-8722